Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Icon Plc","sponsor":"Diamyd Medical AB","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"The 24-Month Follow-Up of DIAGNODE-2 With the Diabetes Vaccine Diamyd\u00ae Will be Presented in Early July","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"IRELAND","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2021","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase II"},{"orgOrder":0,"company":"Icon Plc","sponsor":"Evergreen Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Evergreen Therapeutics Announces Agreement with ICON to Conduct Phase II Clinical Trial for COVID-19 Drug Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"IRELAND","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"June 2021","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I"},{"orgOrder":0,"company":"Icon Plc","sponsor":"BARDA","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ICON Selected By BARDA To Conduct Anthrax Vaccine Clinical Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"IRELAND","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2022","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III"},{"orgOrder":0,"company":"Icon Plc","sponsor":"BARDA","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"BARDA Partners with ICON to Execute Next Generation COVID-19 Vaccines Clinical Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"IRELAND","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2023","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II"}]

    Find Clinical Drug Pipeline Developments & Deals by Icon Plc

    Menu

    Icon Plc

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    DOSSIERs // Finished Dosage Forms

    SERVICES

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Icon Plc

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Ireland
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              BARDA Partners with ICON to Execute Next Generation COVID-19 Vaccines Clinical Trial

              Details:

              The partnership aims to execute a Phase 2b clinical trial to assess the relative efficacy of a next generation COVID-19 vaccine compared to currently approved/authorised COVID-19 vaccines in the prevention of symptomatic, PCR confirmed SARS-CoV-2 infection.

              Lead Product(s): Undisclosed

              Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

              Highest Development Status: Phase II Product Type: Vaccine

              Partner/Sponsor/Collaborator: BARDA

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Partnership September 13, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Icon Plc

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Ireland
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              ICON Selected By BARDA To Conduct Anthrax Vaccine Clinical Trial

              Details:

              This clinical study will inform operational logistics and will not expose participants to anthrax. AV7909 is indicated for post-exposure prophylaxis of anthrax disease. Anthrax vaccine is also recommended for unvaccinated people of all ages who have been exposed to anthrax.

              Lead Product(s): AV7909

              Therapeutic Area: Infections and Infectious Diseases Product Name: AV7909

              Highest Development Status: Phase III Product Type: Vaccine

              Partner/Sponsor/Collaborator: BARDA

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable October 06, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Icon Plc

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Ireland
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Evergreen Therapeutics Announces Agreement with ICON to Conduct Phase II Clinical Trial for COVID-19 Drug Candidate

              Details:

              The purpose of the study is to evaluate the efficacy of Evergreen’s EG-009A drug candidate for the treatment of moderate to severe COVID-19 cases.

              Lead Product(s): EG-009A

              Therapeutic Area: Infections and Infectious Diseases Product Name: EG-009A

              Highest Development Status: Phase I Product Type: Undisclosed

              Partner/Sponsor/Collaborator: Evergreen Therapeutics

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Agreement June 18, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Icon Plc

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Ireland
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              The 24-Month Follow-Up of DIAGNODE-2 With the Diabetes Vaccine Diamyd® Will be Presented in Early July

              Details:

              All 50 patients who participated in the extension of Diamyd Medical's Phase IIb trial DIAGNODE-2 with the diabetes vaccine Diamyd® have now made their 24-month visit, and data will be presented in early July.

              Lead Product(s): Recombinant human glutamic acid decarboxylase,Vitamin D

              Therapeutic Area: Endocrinology Product Name: Diamyd

              Highest Development Status: Phase II Product Type: Vaccine

              Recipient: Diamyd Medical AB

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable April 29, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.
              ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.
              Post Enquiry
              POST ENQUIRY